Get the Stockscreener App
4.00
8.70%
+0.32
After Hours:
4.20
0.20
+5.00%
Autolus Therapeutics plc ADR stock is currently priced at $4.00, with a 24-hour trading volume of 7.72M.
It has seen a +8.70% increased in the last 24 hours and a -29.58% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.72 pivot point. If it approaches the $4.09 resistance level, significant changes may occur.
Previous Close:
$3.68
Open:
$3.68
24h Volume:
7.72M
Market Cap:
$1.06B
Revenue:
-
Net Income/Loss:
$-208.38M
P/E Ratio:
-3.3613
EPS:
-1.19
Net Cash Flow:
$-156.57M
1W Performance:
-4.99%
1M Performance:
-29.58%
6M Performance:
+35.59%
1Y Performance:
+115.05%
1D Range:
$3.625
$4.165
52W Range:
$1.79
$7.45
Autolus Therapeutics plc ADR Stock (AUTL) Company Profile
Name
Autolus Therapeutics plc ADR
Sector
Industry
Phone
44 20 3829 6230
Address
Forest House, 58 Wood Lane White City, London
Autolus Therapeutics plc ADR Stock (AUTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Mar-27-23 | Resumed | Wells Fargo | Overweight |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Jun-14-21 | Upgrade | Jefferies | Hold → Buy |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | JP Morgan | Overweight |
| Jul-22-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Sep-23-19 | Initiated | Needham | Buy |
| May-17-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-24-18 | Initiated | H.C. Wainwright | Buy |
View All
Autolus Therapeutics plc ADR Stock (AUTL) Latest News
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
GlobeNewswire Inc.
Autolus Therapeutics Announces Changes to its Board of Directors
GlobeNewswire Inc.
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
Benzinga
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
GlobeNewswire Inc.
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
GlobeNewswire Inc.
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
Zacks Investment Research
Autolus Therapeutics plc ADR Stock (AUTL) Financials Data
Autolus Therapeutics plc ADR (AUTL) Net Income 2024
AUTL net income (TTM) was -$208.38 million for the quarter ending December 31, 2023, a -40.01% decrease year-over-year.
Autolus Therapeutics plc ADR (AUTL) Cash Flow 2024
AUTL recorded a free cash flow (TTM) of -$156.57 million for the quarter ending December 31, 2023, a -27.14% decrease year-over-year.
Autolus Therapeutics plc ADR (AUTL) Earnings per Share 2024
AUTL earnings per share (TTM) was -$1.20 for the quarter ending December 31, 2023, a +23.57% growth year-over-year.
About Autolus Therapeutics plc ADR
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma. It is also developing AUTO4, a programmed T cell therapy that is in Phase I/II clinical trial for the treatment of peripheral T-cell lymphoma; and AUTO6, a programmed T cell therapy for treating neuroblastoma. Autolus Therapeutics plc has a collaboration partnership with AbCellera Biologics Inc. on antibody discovery project. The company was founded in 2014 and is headquartered in London, the United Kingdom.
3.18%
Cap:
|
Volume (24h):